Current status of atypical antipsychotics for the treatment of fibromyalgia

Drugs of Today

Volumn 50, Issue 6, 2014, Pages 435-444

  Rico Villademoros, Fernando ^a   Calandre, E P ^a   Slim, M ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antipsychotic; Fibromyalgia; Olanzapine; Quetiapine; Ziprasidone

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; ZIPRASIDONE;

AMENORRHEA; ANXIETY; ASTHENIA; COMORBIDITY; CONSTIPATION; DIZZINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FIBROMYALGIA; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MAJOR DEPRESSION; MASTALGIA; NAUSEA; RESTLESSNESS; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE; TREMOR; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC; FIBROMYALGIA; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

ANTIPSYCHOTIC AGENTS; ANXIETY; BENZODIAZEPINES; COMORBIDITY; DEPRESSION; DIBENZOTHIAZEPINES; FIBROMYALGIA; HUMANS; PATIENT SELECTION; PIPERAZINES; SULPIRIDE; THIAZOLES; TREATMENT OUTCOME;

EID: 84903752390     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.6.2127023     Document Type: Review

References (45)

1. Arnold, L.M., Clauw, D.J., McCarberg, B.H, FibroCollaborative. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc 2011, 86(5): 457-64.
2. Queiroz, L.P. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013, 17(8): 356.
3. Yunus, M.B. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat 2012, 2012: 584573.
4. Calandre, E.P., Rico-Villademoros, F., Rodriguez-Lopez, C.M. Monotherapy or combination therapy for fibromyalgia treatment? Curr Rheumatol Rep 2012, 14(6): 568-75.
5. Seidel, S., Aigner, M., Ossege, M., Pernicka, E., Wildner, B., Sycha, T. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2013, 8: CD004844.
6. Depping, A.M., Komossa, K., Kissling, W., Leucht, S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010, 8(12): CD008120.
7. Vulink, N.C., Figee, M., Denys, D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol 2011, 21(6): 429-49.
8. Shah, C., Sharma, T.R., Kablinger, A. Controversies in the use of second generation antipsychotics as sleep agent. Pharmacol Res 2014, 79: 1-8.
9. Möller, H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality . Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(7): 1101-11.
10. Abbas, A.I., Hedlund, P.B., Huang, X.P., Tran, T.B., Meltzer, H.Y., Roth, B.L. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009, 205(1): 119-28.
11. Maina, G., Vitalucci, A., Gandolfo, S., Bogetto, F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002, 63(1): 38-43. (Pubitemid 34113485)
12. Bogetto, F., Bonatto Revello, R., Ferro, G., Maina, G., Ravizza, L. Psychopharmacological treatment of Burning Mouth Syndrome (BMS). A study sample of 121 patients. [Trattamento psicofarmacologico della Burning Mouth Syndrome (BMS): Studio su di un campione di 121 pazienti]. Minerva Psichiatrica 1999, 40(1): 1-10. (Pubitemid 29174169)
13. Rico-Villademoros, F., Rodriguez-Lopez, C.M., Morillas-Arques, P., Vilchez, J.S., Hidalgo, J., Calandre, E.P. Amisulpride in the treatment of fibromyalgia: an uncontrolled study. Clin Rheumatol 2012, 31(9): 1371-5.
14. Stahl, S.M., Shayegan, D.K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003, 64 (Suppl. 19): 6-12.
15. Calandre, E.P., Hidalgo, J., Rico-Villademoros, F. Use of ziprasidone in patients with fibromyalgia: a case series. Rheumatol Int 2007, 27(5): 473-6. (Pubitemid 46294988)
16. 1-adrenergic receptors in vitro. Schizophr Res 1999, 37(1): 107-22.
17. Zhang, W., Bymaster, F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 1999, 141(3): 267-78. (Pubitemid 29196076)
18. Khojainova, N., Santiago-Palma, J., Kornick, C., Breitbart, W., Gonzales, G.R. Olanzapine in the management of cancer pain. J Pain Symptom Manage 2002, 23(4): 346-50. (Pubitemid 34462947)
19. Silberstein, S.D., Peres, M.F., Hopkins, M.M., Shechter, A.L., Young, W.B., Rozen, T.D. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002, 42(6): 515-8. (Pubitemid 37011824)
20. Gorski, E.D., Willis, K.C. Report of three case studies with olanzapine for chronic pain. J Pain 2003, 4(3): 166-8. (Pubitemid 36523436)
21. Kiser, R.S., Cohen, H.M., Freedenfeld, R.N., Jewell, C., Fuchs, P.N. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage 2001, 22(2): 704-8. (Pubitemid 32725813)
22. Corallo, F., Italiano, D., Bonanno, L., Baglieri, A., Marino, S., Bramanti, P. Olanzapine treatment improved quality of life in a patient with fibromyalgia syndrome: a psychological evaluation. Acta Reumatol Port 2011, 36(3): 311-2.
23. Rico-Villademoros, F., Hidalgo, J., Dominguez, I., García-Leiva, J.M., Calandre, E.P. Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(1): 161-4. (Pubitemid 40021786)
24. Freedenfeld, R.N., Murray, M., Fuchs, P.N., Kiser, R.S. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract 2006, 6(2): 112-8. (Pubitemid 43676681)
25. Goldstein, J.M. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc) 1999, 35(3): 193-210. (Pubitemid 29238943)
26. López-Muñoz, F., Alamo, C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry 2013, 4: 102.
27. Cohrs, S., Rodenbeck, A., Guan, Z., Pohlmann, K., Jordan, W., Meier, A., Rüther, E. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004, 174(3): 421-9. (Pubitemid 39044301)
28. Gedge, L., Lazowski, L., Murray, D., Jokic, R., Milev, R. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatr Dis Treat 2010, 6: 501-8.
29. th Annu Meet Am Neuropsych Assoc (February 2-4, Hawaii) 2003] 2003, 15(2): Abst P100.
30. Hidalgo, J., Rico-Villademoros, F., Calandre, E.P. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(1): 71-7. (Pubitemid 44959248)
31. Calandre, E.P., Morillas-Arques, P., Rodriguez-Lopez, C.M., Rico-Villademoros, F., Hidalgo, J. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry 2007, 40(2): 68-71. (Pubitemid 46697677)
32. Potvin, S., Morin, M., Cloutier, C., Gendron, A., Bissonnette, A., Marchand, S. Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol 2012, 32(5): 684-7.
33. Mcintyre, A., Paisley, D., Kouassi, E., Gendron, A. Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. Arthritis Rheumatol 2014, 66(2): 451-61.
34. Calandre, E.P., Rico-Villademoros, F., Galán J. et al. Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology (Berl) 2014, 231(12): 2525-31.
35. th Annu Meet Am Psychiatr Assoc (May 14-18, Honolulu) 2011, Abst Nr8-48.
36. Barkhuizen, A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002, 28(2): 261-90.
37. Yunus, M.B. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis rheum 2008, 37(6): 339-52.
38. Smith, H.S., Harris, R., Clauw, D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 2011, 14(2): e217-45.
39. Wu, C.H., Farley, J.F., Gaynes, B.N. The association between antidepressant dosage titration and medication adherence among patients with depression. Depress Anxiety 2012, 29(6): 506-14.
40. Calandre, E.P., Morillas-Arques, P., Molina-Barea, R., Rodriguez-Lopez, C.M., Rico-villademoros, F. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord 2011, 12: 95.
41. Straube, S., Derry, S., Moore, R.A., McQuay, H.J. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010, 49(4): 706-15.
42. Häuser, W., Bernardy, K., Uçeyler, N., Sommer, C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin-a meta-analysis of randomized controlled trials. Pain 2009, 145(1-2): 69-81.
43. Chiesa, A., Chierzi, F., De Ronchi, D., Serretti, A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012, 27(2): 76-90.
44. Maneeton, N., Maneeton, B., Srisurapanont, M., Martin, S.D. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry 2012, 12: 160.
45. Bauer, M., El-Khalili, N., Datto, C., Szamosi, J., Eriksson, H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010, 127(1-3): 19-30.